VIVA BIOTECH HOLDINGS
维亚生物科技控股集团

(Incorporated in the Cayman Islands as an exempted company with limited liability)
(Stock code: 1873)

POSITIVE PROFIT ALERT

This announcement is made by Viva Biotech Holdings (the "**Company**", together with its subsidiaries, collectively referred to as the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company ("**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group and information currently available, it is expected that the revenue of the Group for the year ended December 31, 2019 (the "**Year**") will increase by more than 50% as compared to the corresponding period in 2018, and the net profit for the Year will increase by more than 180% as compared to the corresponding period in 2018. Such significant increases are mainly attributable to (1) the mutual contribution of our innovative and twin drivers of cash-for-service (CFS) business and the equity-for-service (EFS) business; (2) rapid growth in customer number and contract orders and the continuing expansion of our incubation portfolio companies; and (3) progress in the research and development and financing of our incubation portfolio companies resulting in partial disposal of certain incubation portfolio companies.

As the Company is in the process of finalizing the consolidated financial results of the Group for the Year, the information contained in this announcement is based on the current information available to the Board and the preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group for the Year, which is subject to finalization and other potential adjustments (if any) and have not been reviewed or confirmed by the auditor or the audit committee of the Company. Details of the Group's performance will be disclosed in the Company's announcement of the audited annual results of the Group for the Year, which will be announced before the end of March 2020 in compliance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Executive Director

Hong Kong, March 16, 2020

As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; two Non-executive Directors, namely, Ms. Mao Jun and Mr. John Wu Jiong; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.